Physical Training for People With Parkinson's Disease and Multiple Sclerosis: Effect on Mind and Body
NCT05357638, Not applicable, Unknown, Amsterdam UMC, location VUmc
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Physical Training for People With Parkinson's Disease and Multiple Sclerosis: Effect on Mind and Body | ClinicalTrials.gov |
| NCT number | NCT05357638 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 48 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Amsterdam UMC, location VUmc | ClinicalTrials.gov |
| Conditions | Parkinson Disease, Multiple Sclerosis | ClinicalTrials.gov |
| Interventions | High Intensity Interval Training (HIIT), Continuous Aerobic Training (CAT), Movement Advice | ClinicalTrials.gov |
| First posted | 2022-05-03 | ClinicalTrials.gov |
| Last updated | 2023-04-25 | ClinicalTrials.gov |
Registered outcomes 25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in anxiety and depressive symptoms | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on anxiety and depressive symptoms, measured by the Hospital Anxiety and Depression Scale | ClinicalTrials.gov |
| Secondary | Change in disease severity | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on disease severity, measured by the Unified Parkinson's Disease Rating Scale (Parkinson's disease) (total score range 0-199, higher score = worse) or Expanded Disability Status Scale (Multiple Sclerosis) | ClinicalTrials.gov |
| Secondary | Change in cognitive function (i.e., ability to inhibit cognitive interference) | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on cognitive function, measured by the Stroop Color Word Test | ClinicalTrials.gov |
| Secondary | Change in cognitive function (i.e., mental flexibility) | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on cognitive function, measured by the Trail Making Test | ClinicalTrials.gov |
| Secondary | Change in cognitive function (i.e., range of cognitive operations: motor speed, attention, and visuoperceptual functions) | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on cognitive function, measured by the Symbol Digit Modalities Test | ClinicalTrials.gov |
| Secondary | Change in fatigue | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on fatigue, measured by the Checklist Individual Strength fatigue sub-scale | ClinicalTrials.gov |
| Secondary | Change in sleep quality | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on sleep quality, measured by the Insomnia Severity Index | ClinicalTrials.gov |
| Secondary | Change in well-being | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on well-being, measured by the Parkinson's Disease Questionnaire (8 items) (Parkinson's disease) or Multiple Sclerosis Impact Scale (29 items) (Multiple Sclerosis) | ClinicalTrials.gov |
| Secondary | Change in quality of life | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on quality of life, measured by the Short Form health survey (36 items) | ClinicalTrials.gov |
| Secondary | Change in motor capacity (i.e., walking speed) | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on motor capacity, measured by the 10-Meter Walk Test | ClinicalTrials.gov |
| Secondary | Change in motor capacity (i.e., lower extremity function, mobility, and fall risk) | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on motor capacity, measured by the Timed Up and Go test | ClinicalTrials.gov |
| Secondary | Change in motor capacity (i.e., finger dexterity) | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on motor capacity, measured by the Nine Hole Peg Test | ClinicalTrials.gov |
| Secondary | Change in activities of daily living | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on activities of daily living, measured by the Nottingham Extended Activities of daily living Index | ClinicalTrials.gov |
| Secondary | Change in biomarkers of neuroplasticity in blood | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on biomarkers of neuroplasticity in blood, measured by Brain Derived Neurotrophic Factor concentration | ClinicalTrials.gov |
| Secondary | Change in biomarkers of neurodegeneration in blood | Baseline (week 0), week 4, week 12, week 16 | The effect of physical training on biomarkers of neurodegeneration in blood, measured by Neurofilament Light concentration | ClinicalTrials.gov |
| Secondary | Change in brain morphology | Week 4, week 12 | The effect of physical training on brain morphology, measured by structural magnetic resonance imaging (MRI) | ClinicalTrials.gov |
| Secondary | Change in structural brain connectivity | Week 4, week 12 | The effect of physical training on structural brain connectivity, measured by diffusion MRI + free-water content | ClinicalTrials.gov |
| Secondary | Change in brain connectivity | Week 4, week 12 | The effect of physical training on brain connectivity, measured by resting state functional MRI | ClinicalTrials.gov |
| Secondary | Change in brain iron concentration in the Substantia Nigra | Week 4, week 12 | The effect of physical training on brain iron concentration in the Substantia Nigra, measured by Quantitative Susceptibility Mapping methodology | ClinicalTrials.gov |
| Secondary | Change in brain neuromelanin content | Week 4, week 12 | The effect of physical training on brain neuromelanin content, measured by neuromelanin-sensitive MRI | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)